October 5, 2022 — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of the late-breaking science session at the upcoming 2022 American Heart Association (AHA) Scientific Sessions taking place November 5-7, 2022, virtually and in Chicago, Illinois. Baxdrostat is a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase. The presentation will include clinical data from CinCor’s BrigHtn trial, a Phase 2 randomized, double-blind, multicenter, placebo-controlled dose-ranging study designed to assess the safety and efficacy of baxdrostat in subjects who have not achieved their target blood pressure despite receiving three or more antihypertensive agents at their maximally tolerated doses, one of which must be a diuretic.
“We believe baxdrostat provides the first new mechanism to lower aldosterone levels for the treatment of hypertension since the development of ACEIs and ARBs over 30 years ago,” said Mason Freeman, M.D., Chief Medical Officer at CinCor. “We are pleased to present data from our BrigHtn trial demonstrating baxdrostat can potentially be used in combination with those older agents to provide greater blood pressure lowering in patients whose hypertension is refractory to treatment.”
Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Treatment-Resistant Hypertension
Date/Time: November 7, 2022
Presenter: Mason Freeman M.D, Chief Medical Officer at CinCor
Session Title: LBS.09 - Late-Breaking Science: Resistant Hypertension: A Pressure Cooker
Please visit the AHA Scientific Sessions Late-Breaking Science for the most current programming.
For more information: https://www.cincor.com/
July 24, 2024 
